Mark Dainty
MPharm, FCA · Portfolio Manager
Precision Medicine is the fundamental revolution in drug discovery and patient treatment of the 21st century. Traditional medicine is being transformed into patient specific solutions that treat disease at its underlying cause. This intersection of a genomic and biotechnology revolution is changing lives, now.
Bluebox team
MPharm, FCA · Portfolio Manager
Portfolio Manager BBPM
“Over 25 years ago, medicine sparked my curiosity. Combining that passion with investing in the era of Precision Medicine is a privilege and a joy.”
BlueBox Investment Strategy
Precision Medicine is a transformational change in what humanity can do to improve people's lives. It is a more targeted approach to medicine than the one-size-fits-all methods of the last 100+ years. Precision Medicine is only possible due to a confluence of major advances in genomics, molecular biology, biotechnology, chemistry and computing power. This wave of innovation has accelerated through the last 20 years and we expect decades of growth ahead as scientists knowledge grows.
We expect Precision Medicine to lead to greater predictability and better returns for companies and society at large. We invest in companies that are developing, selling or enabling precision medicine and creating substantial value for their outside shareholders.
Experts in what we do
We normally hold 25 to 45 positions with a maximum weight of 10%, targeting mainly companies between $1 billion and $80 billion market cap. The fund is not benchmark oriented, keeps a low turnover in its positions and cash at minimum, usually below 10%. The UCITS Fund launched on 28 February 2023.
Thanks to advances in genomics, computing and biotechnology we can now target medicines to a patient's specific disease driver, instead of using a one-size-fits-all approach. This change started in the 1990's but really accelerated from 2010, first in rare genetic disease and certain cancers. There is a long way to go in just these areas, but decades of growth as we start breaking down more common diseases to actionable subtypes.
The primary focus is companies that develop, make, sell or enable Precision Medicines. A critical combination of science and holistic company analysis is key to our stock selection process.
We focus on maximizing returns through a focus on companies developing, selling, making or enabling Precision Medicine. We prefer multi-asset companies and look for barriers to entry, a strong strategy for the whole value chain and sustainable business models. We control the level of risk inherent in development stage companies through individual position sizes and at the portfolio level. Investing in enablers of Precision Medicine is a key part of our portfolio construction process.
| Date | Value (USD) |
|---|---|
| 12/08/2026 | 1,868.74 |
| 24/08/2026 | 1,921.24 |
| 03/09/2026 | 1,883.69 |
| 15/09/2026 | 1,776.66 |
| 28/09/2026 | 1,779.20 |
| 08/10/2026 | 1,677.37 |
| 20/10/2026 | 1,754.34 |
| 30/10/2026 | 1,761.25 |
| 12/11/2026 | 1,749.31 |
| Date | Value (USD) |
|---|---|
| 12/05/2026 | 1,565.52 |
| 09/06/2026 | 1,567.84 |
| 06/07/2026 | 1,877.58 |
| 29/07/2026 | 1,772.20 |
| 19/08/2026 | 1,940.44 |
| 09/09/2026 | 1,822.41 |
| 30/09/2026 | 1,774.08 |
| 21/10/2026 | 1,757.82 |
| 12/11/2026 | 1,749.31 |
| Date | Value (USD) |
|---|---|
| 06/01/2026 | 1,612.96 |
| 11/02/2026 | 1,585.81 |
| 18/03/2026 | 1,501.28 |
| 28/04/2026 | 1,523.45 |
| 15/06/2026 | 1,598.47 |
| 27/07/2026 | 1,778.66 |
| 01/09/2026 | 1,883.32 |
| 06/10/2026 | 1,713.95 |
| 12/11/2026 | 1,749.31 |
| Date | Value (USD) |
|---|---|
| 28/02/2023 | 1,000.00 |
| 17/08/2023 | 1,012.37 |
| 31/01/2024 | 1,173.78 |
| 17/07/2024 | 1,300.11 |
| 06/01/2025 | 1,248.61 |
| 24/06/2025 | 1,126.22 |
| 04/12/2025 | 1,625.15 |
| 28/05/2026 | 1,590.12 |
| 12/11/2026 | 1,749.31 |
| Date | Value (USD) |
|---|---|
| 12/11/2025 | 1,500.21 |
| 29/12/2025 | 1,610.30 |
| 12/02/2026 | 1,564.97 |
| 25/03/2026 | 1,514.54 |
| 13/05/2026 | 1,570.62 |
| 07/07/2026 | 1,907.82 |
| 20/08/2026 | 1,912.63 |
| 30/09/2026 | 1,774.08 |
| 12/11/2026 | 1,749.31 |
lorem IPSUM
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Q&A
Have further questions about the fund, click on the video below to hear Mark Dainty briefly review key topics, such as: An overview of the Fund. How this fund is different? What is Precision Medicine? What is the impact of Precision Medicine? What we look for in an investment? The portfolio manager's experience in the sector?